1. Home
  2. STXS vs TVGN Comparison

STXS vs TVGN Comparison

Compare STXS & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stereotaxis Inc.

STXS

Stereotaxis Inc.

N/A

Current Price

$1.32

Market Cap

139.3M

Sector

Health Care

ML Signal

N/A

Logo Tevogen Bio Holdings Inc.

TVGN

Tevogen Bio Holdings Inc.

N/A

Current Price

$7.70

Market Cap

21.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
STXS
TVGN
Founded
1990
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
139.3M
21.3M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
STXS
TVGN
Price
$1.32
$7.70
Analyst Decision
Strong Buy
Hold
Analyst Count
2
1
Target Price
$4.00
N/A
AVG Volume (30 Days)
486.8K
7.0K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
16.67
N/A
EPS
N/A
N/A
Revenue
$29,346,617.00
N/A
Revenue This Year
$28.22
N/A
Revenue Next Year
$30.47
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.24
$0.14
52 Week High
$3.59
$12.03

Technical Indicators

Market Signals
Indicator
STXS
TVGN
Relative Strength Index (RSI) 40.91 68.64
Support Level $1.30 $6.41
Resistance Level $1.51 $10.59
Average True Range (ATR) 0.06 0.34
MACD -0.00 0.05
Stochastic Oscillator 22.45 88.89

Price Performance

Historical Comparison
STXS
TVGN

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

About TVGN Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.

Share on Social Networks: